These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 23672349)

  • 41. Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
    Mascarenhas J
    Leuk Lymphoma; 2015; 56(9):2493-7. PubMed ID: 25586607
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.
    Verstovsek S; Kiladjian JJ; Vannucchi AM; Mesa RA; Squier P; Hamer-Maansson JE; Harrison C
    Cancer; 2023 Jun; 129(11):1681-1690. PubMed ID: 36840971
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
    Lancman G; Mascarenhas J
    Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
    Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
    J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
    Verstovsek S; Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Jones M; Kornacki D; Sun K; Kantarjian H;
    J Hematol Oncol; 2017 Feb; 10(1):55. PubMed ID: 28228106
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clarifying the use of ruxolitinib in patients with myelofibrosis.
    Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
    Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Raza A; Vaddi K; Sun W; Peng W; Sandor V; Kantarjian H;
    Haematologica; 2015 Apr; 100(4):479-88. PubMed ID: 25616577
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New Concepts of Treatment for Patients with Myelofibrosis.
    Bose P; Alfayez M; Verstovsek S
    Curr Treat Options Oncol; 2019 Jan; 20(1):5. PubMed ID: 30675650
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
    Kvasnicka HM; Thiele J; Bueso-Ramos CE; Sun W; Cortes J; Kantarjian HM; Verstovsek S
    J Hematol Oncol; 2018 Mar; 11(1):42. PubMed ID: 29544547
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ruxolitinib.
    Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
    Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
    [TBL] [Abstract][Full Text] [Related]  

  • 51. How many JAK inhibitors in myelofibrosis?
    Ferreira BV; Harrison C
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emerging drugs for myelofibrosis.
    Atallah E; Verstovsek S
    Expert Opin Emerg Drugs; 2012 Dec; 17(4):555-70. PubMed ID: 23186315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.
    Verstovsek S; Parasuraman S; Yu J; Shah A; Kumar S; Xi A; Harrison C
    Ann Hematol; 2022 Jan; 101(1):131-137. PubMed ID: 34625831
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ruxolitinib for myelofibrosis.
    Diamantidis MD
    N Engl J Med; 2012 May; 366(21):2031; author reply 2032-4. PubMed ID: 22621633
    [No Abstract]   [Full Text] [Related]  

  • 55. Ruxolitinib for myelofibrosis.
    Koschmieder S; Koppelle A; Seifert H
    N Engl J Med; 2012 May; 366(21):2031-2; author reply 2032-4. PubMed ID: 22621634
    [No Abstract]   [Full Text] [Related]  

  • 56. Ruxolitinib for myelofibrosis.
    Haznedaroglu IC
    N Engl J Med; 2012 May; 366(21):2032; author reply 2032-5. PubMed ID: 22621635
    [No Abstract]   [Full Text] [Related]  

  • 57. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
    Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
    Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Verruconis gallopava in a patient with myelofibrosis on ruxolitinib.
    Hsu A; Ulici V
    Blood; 2020 Apr; 135(14):1189. PubMed ID: 32243521
    [No Abstract]   [Full Text] [Related]  

  • 59. How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.
    Massaro F; Molica M; Breccia M
    Expert Rev Hematol; 2017 Feb; 10(2):155-159. PubMed ID: 27983880
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation.
    Barabanshikova MV; Zubarovsky IN; Savrasov VM; Korolkov AJ; Baykov VV; Botina AV; Vlasova JJ; Moiseev IS; Darskaya EI; Morozova EV; Afanasyev BV
    Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):140-145. PubMed ID: 30978308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.